

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Herrick, Christina Anne		POSITION TITLE Associate Professor of Dermatology	
eRA COMMONS USER NAME (credential, e.g., agency login) CHERRICK			
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
Rutgers College, New Brunswick, NJ	B.A.	1986	Biology
SUNY-Downstate Medical Center, Brooklyn, NY	M.D., Ph.D.	1993	Medicine/Pathology
Yale University School of Medicine	Postdoct.	1997-1999	Immunology

A. Positions and Honors.

Positions and Employment

- 1993-1994 Internship, Internal Medicine, Yale-New Haven Hospital, New Haven, CT
- 1994-1997 Dermatology Residency, Yale University School of Medicine, New Haven, CT
- 1999-2000 Instructor, Department of Dermatology; Yale University School of Medicine
- 1999-2007 Instructor, Department of Immunobiology; Yale University School of Medicine
- 2000-2007 Assistant Professor, Department of Dermatology, Yale University School of Medicine
- 2007-present Associate Professor, Department of Dermatology, Yale University School of Medicine

Professional Societies

- The American Academy of Dermatology, 1994 – present
- Women’s Dermatologic Society, 1994 - present
- The Society for Investigative Dermatology, 1994 – present
- Dermatology Foundation, 1998 - present

Honors

- 1997 Women’s Dermatologic Society Mentorship Award (for study of treatment of atopic dermatitis with Dr. Jon Hanifin at The Oregon Health Sciences University, Portland, OR)
- Medical School: Alpha Omega Alpha; Cum Laude

B. Peer-reviewed publications (in chronological order).

1. **Herrick, CA**, MC Smith, K Wagner, C Heusser and HG Durkin. Recombinant interferon gamma medicated dose dependent regulation of hapten specific IgE anamnestic responses induced in vitro: Lack of effect of recombinant interleukin-4. *EOS-J Immunol Immunopharmacol* 1990;X(n):166.
2. **Herrick CA**, JA Carucci, GI Kleiner and HG Durkin. Regulation of hapten-specific memory IgE responses induced in vitro. Requirement for both Thy-1+ AsGM1+ and Thy-1+ AsGM1- cells and for IFN-alpha and IL-4. *J Immunol* 1993;151:3440.

3. Carucci JA, **CA Herrick**, and HG Durkin. Neuropeptide-mediated regulation of hapten-specific IgE responses in mice. II. Mechanisms of substance P-mediated isotype-specific suppression of BPO-specific IgE antibody-forming cell responses induced in vitro. *J Neuroimmunol* 1994;49:89.
4. Carucci JA, DL Auci, **CA Herrick**, and HG Durkin. Neuropeptide-mediated regulation of hapten-specific IgE responses in mice. I. Substance P-mediated isotype-specific suppression of BPO-specific IgE antibody-forming cell responses induced in vivo and in vitro. *J Leukoc Biol* 1995;57:110.
5. **Herrick, CA**, H MacLeod, E Glusac, RE Tigelaar and K Bottomly. Th2 Responses Induced by Epicutaneous versus Inhalational Protein Exposure are Differentially Dependent on IL-4. *J Clin Invest* 2000;105:765.
6. Wisnewski, AV, R Srivastava, **C Herrick**, L Xu, R Lemus, H Cain, NM Magoski, MH Karol, K Bottomly, and CA Redlich. Identification of Human Lung and Skin Proteins Conjugated with Hexamethylene Diisocyanate In Vitro and In Vivo. *Am J Respir Crit Care Med* 2000;162:2330-2336.
7. Cohn, L, **C Herrick**, N Niu, RJ Homer, and K Bottomly. IL-4 Promotes Airway Eosinophilia by Suppressing IFN- γ Production: Defining a Novel Role for IFN- γ in the Regulation of Allergic Airway Inflammation. *J Immunol* 2001;166: 2760-2767.
8. **Herrick, CA**, L Xu, AV Wisnewski, J Das, CA Redlich, and K Bottomly. A novel mouse model of diisocyanate-induced asthma showing allergic-type inflammation in the lung after inhaled antigen challenge. *J Allergy Clin Immunol* 2002;109:873-878.
9. Constant, SL, JL Brogdon, DA Piggott, **CA Herrick**, I Visintin, NH Ruddle, and K Bottomly. Resident lung antigen-presenting cells have the capacity to promote Th2 T cell differentiation in situ. *J Clin Invest* 2002;110: 1441-1448.
10. Eisenbarth, SC, DA Piggott, JW Huleatt, I Visintin, **CA Herrick**, and K Bottomly. Lipopolysaccharide-enhanced, Toll-like Receptor 4-dependent T Helper Cell Type 2 Responses to Inhaled Antigen. *J Exp Med* 2002;196:1-8.
11. **Herrick, CA**, L Xu, ANJ McKenzie, RE Tigelaar, and K Bottomly. IL-13 is necessary, not simply sufficient, for epicutaneously induced Th2 responses to soluble protein antigen. *J Immunol* 2003;170:2488-95.
12. **Herrick, CA** and K Bottomly. To respond or not to respond: T cells in allergic asthma. *Nature Reviews Immunology* 2003;3:405-412
13. **Herrick, CA**, J Das, L Xu, AV Wisnewski, CA Redlich, and K Bottomly. Differential roles for CD4 and CD8 T cells following diisocyanate sensitization: Genetic control of Th2-induced lung inflammation. *J Allergy Clin Immunol* 2003;111:1087-1094.
14. Wisnewski, AV, **CA Herrick**, Q Liu, L Chen, K Bottomly, and C Redlich. Human γ/δ T cell proliferation and IFN- γ production induced by hexamethylene diisocyanate. *J Allergy Clin Immunol* 2003;112:538-546.
15. Eisenbarth, SC, A Zhadkevich, P Ranney, **CA Herrick**, and K Bottomly. IL-4-dependent Th2 collateral priming to inhaled antigens independent of toll-like receptor 4 and myeloid differentiation factor 88. *J Immunol.* 2004;172:4527-34.
16. Piggott DA, SC Eisenbarth, L Xu, SL Constant, JW Huleatt, **CA Herrick**, and K Bottomly. MyD88-dependent induction of allergic Th2 responses to intranasal antigen. *J Clin Invest.* 2005;115:459-467.
17. Bello D, **Herrick CA**, Smith TJ, Woskie SR, Streicher RP, Cullen MR, Liu Y, Redlich CA. Skin Exposure to Isocyanates: Reasons for Concern *Environ Health Perspect.* 2006;115:328-335.
18. Redlich CA, and **CA Herrick**. Lung/skin connections in occupational lung disease. *Curr Opin Allergy Clin Immunol.* 2008;8(2):115-9.
19. Dokmeci E, and **CA Herrick**. The immune system and atopic dermatitis. *Semin Cutan Med Surg.* 2008; 27:138-43.

C. Research Support
Ongoing Research Support

R01 AR050628-01 Herrick (PI) 4/1/06 - 3/31/11
NIH/NIAID
Th2 Responses in the Cutaneous Environment

The Aims of this project include investigation of the requirement for IL-13 during generation of Th2 type immune responses to a protein antigen in the cutaneous environment by identifying the relevant source(s) and target(s) of IL-13, as well determining the role of innate immune system receptors in these responses.

R01 HL054450-13 Herrick (PI) 12/10/94 – 2/28/09*
NIH/NHLBI
Immunopathogenesis of Airway Inflammation

The overall goal of this proposal is to understand the cellular and molecular factors that regulate dendritic cell activation in response to aeroallergens. The specific aims are: 1) To determine the mechanism by which low dose lipopolysaccharide induces Th2 priming following inhaled antigen; and 2) To determine the role of IL-13 in Th2 priming.

* The original PI on this grant was Kim Bottomly, with C. Herrick as a co-investigator. The grant was transferred to C. Herrick upon Dr. Bottomly's departure from Yale, effective 9/1/07.

Yale-BIPI Research Alliance Pilot Project Herrick (PI) 9/1/07 – 8/31/08
Boehringer-Ingelheim Pharmaceuticals
Mouse model of T cell subset-mediated cutaneous inflammatory responses

This is a pilot project aimed at establishing a novel model of T cell-mediated cutaneous inflammation, utilizing an adoptive transfer T cell receptor transgenic system to analyze the roles of various T cell subsets.